Stockscreener 앱 받기
0.85
6.48%
-0.0589
시간 외 거래:
.84
-0.01
-1.18%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
Panic Selling: Is NeuroSense Therapeutics Ltd still a buy after recent gains2025 Buyback Activity & Daily Volume Surge Signals - baoquankhu1.vn
Activity Recap: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Earnings Miss: What is VCICs valuation compared to sector2025 Momentum Check & Real-Time Price Movement Reports - baoquankhu1.vn
Gap Down: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesTrade Exit Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
What are NeuroSense Therapeutics Ltd. Equity Warrant’s recent SEC filings showingStop Loss & Weekly High Conviction Ideas - mfd.ru
ALS drug PrimeC cuts death risk by 65% - Longevity.Technology
Is NeuroSense Therapeutics Ltd. Equity Warrant stock safe for conservative investorsPortfolio Value Report & Long-Term Safe Investment Ideas - mfd.ru
Aug Chart Watch: Does NeuroSense Therapeutics Ltd Equity Warrant align with a passive investing strategyJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis - MarketBeat
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - Finviz
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
NeuroSense Reports 65% Lower Mortality Risk and 14-Month Survival Gain for PrimeC in ALS Trial - TipRanks
Published on: 2026-02-18 21:38:58 - baoquankhu1.vn
ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan
Buyout Rumor: Whats the analyst consensus on Invesco Mortgage Capital IncPortfolio Gains Report & Weekly High Return Stock Forecasts - baoquankhu1.vn
How NeuroSense Therapeutics Ltd. stock reacts to global recession fearsJuly 2025 Short Interest & Verified Stock Trade Ideas - mfd.ru
NeuroSense Provides Business Update and Progress for the First Half of 2025 - Intellectia AI
Why is NeuroSense Therapeutics Ltd. stock going downMarket Volume Summary & Daily Risk Controlled Trade Plans - mfd.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock could be next big winner2025 EndofYear Setup & Weekly High Return Forecasts - mfd.ru
Is NeuroSense Therapeutics Ltd. stock supported by strong fundamentalsPortfolio Gains Summary & Weekly High Conviction Trade Ideas - mfd.ru
Will NeuroSense Therapeutics Ltd. (H1Z) stock enhance shareholder valueWeekly Investment Report & Pattern Based Trade Signal System - mfd.ru
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase - TipRanks
Published on: 2026-02-13 23:05:19 - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stock2025 Technical Patterns & Weekly Top Gainers Alerts - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
What are the risks of holding NeuroSense Therapeutics Ltd. Equity Warrant2025 Bull vs Bear & High Accuracy Investment Signals - mfd.ru
Is NeuroSense Therapeutics Ltd. Equity Warrant forming a bullish divergenceWeekly Trade Summary & Weekly Chart Analysis and Guides - mfd.ru
Wall Street Recap: How do insiders feel about Prelude Therapeutics IncorporatedQuarterly Performance Summary & Free High Return Stock Watch Alerts - baoquankhu1.vn
MACD Signal: Whats the fair value of NeuroSense Therapeutics Ltd stockAnalyst Upgrade & Weekly Momentum Picks - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. Equity Warrant stock recession proof2025 Performance Recap & High Return Trade Opportunity Guides - mfd.ru
Neurosense Therapeutics stock rises after securing Australian patent for PrimeC - Investing.com Nigeria
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042 - TipRanks
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - Nasdaq
Does NeuroSense Therapeutics Ltd. Equity Warrant have strong fundamentalsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
How interest rate cuts could boost NeuroSense Therapeutics Ltd. stock2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Fund Flows: Can VTLE disrupt its industryQuarterly Market Review & Weekly Hot Stock Watchlists - baoquankhu1.vn
Market Rankings: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETFQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is now the right time to enter Tectonic Therapeutic IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Buyback Watch: Is HSDT a play on infrastructure spending2025 Volume Leaders & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Buy: Is SPGPRJ undervalued by DCF analysisJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Retail: Will TILE benefit from seasonality2025 Valuation Update & Daily Growth Stock Tips - baoquankhu1.vn
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
Analyst Calls: Is NeuroSense Therapeutics Ltd gaining market sharePortfolio Value Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Gainers: Is RCKY stock a value trapJuly 2025 PostEarnings & Reliable Entry Point Alerts - baoquankhu1.vn
Portfolio Shifts: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingJuly 2025 Update & Long-Term Capital Growth Ideas - baoquankhu1.vn
Big Picture: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Ideas Watch: Will NeuroSense Therapeutics Ltd face regulatory challengesWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Weekly Trades: Why is NeuroSense Therapeutics Ltd stock going downInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Aug Highlights: Is SNOA likely to announce a buybackIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - ulpravda.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
2.90%
2.73%
자본화:
|
볼륨(24시간):